LAEKNA-B (02105) has disclosed its interim results for the six months ended June 30, 2026. The group recorded other income of RMB 25.962 million, representing a year-on-year increase of 30.41%. Research and development expenses amounted to RMB 97 million, down 7.79% from the prior corresponding period, while the loss for the period narrowed to RMB 2.549 million, a substantial reduction of 98.03% year-on-year.
According to the announcement, other income rose by RMB 6.1 million, or 30.7%, from RMB 19.9 million in the first half of 2025 to RMB 26 million in the reporting period, primarily driven by higher interest income on bank deposits.
LAE102 is a wholly self-developed monoclonal antibody targeting ActRIIA. By blocking the Activin-ActRII pathway, it promotes muscle regeneration and reduces fat, positioning LAE102 as a highly promising drug candidate for weight management while preserving muscle mass. Meanwhile, LAE103 is a selective ActRIIB antibody, and LAE123 is a dual-antagonist monoclonal antibody targeting ActRIIA/IIB. Both are self-developed antibodies intended for muscle and other disease indications. The group has established a comprehensive ActRII product portfolio, aiming to maximize the developmental value of targeting ActRII receptors. Currently, the company is rapidly advancing the clinical development of this portfolio while actively seeking strategic partners to accelerate overall development and commercialization efforts. Additionally, the group is exploring potential combination therapy opportunities between pipeline products and existing approved drugs or conventional treatments.
The combination trial of the company's LAE002 (afuresertib) with fulvestrant has demonstrated significant clinical value in treating HR+/HER2- breast cancer patients who have progressed after prior standard endocrine or anti-estrogen therapies, including CDK4/6 inhibitors. This area represents a substantial unmet medical need with vast market potential. Similarly, the combination of LAE002 (afuresertib) with LAE001 (lapiteronel) has shown favorable therapeutic benefits in patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to second-generation androgen or androgen receptor (A/AR) targeting drugs.
AstraZeneca's Capivasertib (Truqap) is the world's first approved AKT inhibitor. Following its initial approval in November 2023 for HR+/HER2- breast cancer, the US FDA granted approval in June 2026 for capivasertib (Truqap) in combination with abiraterone and prednisone for the treatment of PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). These approvals have significantly broadened the therapeutic scope of AKT inhibitors and underscored their potential in addressing unmet medical needs across multiple tumor types.
The company is committed to fully unlocking the clinical potential of its pipeline products. During the reporting period, the group successfully completed the Phase I SAD study of LAE102 in the United States in collaboration with Eli Lilly. In June 2026, the group entered into an exclusive license agreement with Vasque Bio, granting Vasque Bio (along with other rights) an exclusive license within a defined territory to develop, manufacture, commercialize, and otherwise develop LAE118. In 2025, the group signed an exclusive license agreement with Qilu Pharmaceutical for LAE002 (afuresertib) in China, aimed at accelerating the regulatory approval and commercialization process of LAE002 (afuresertib) while maximizing its commercial value.
Looking ahead, the company will continue to seek strategic partnerships with leading pharmaceutical companies to advance the clinical development and commercialization of its drug candidate assets. The group aims to initiate IND-enabling studies for LAE124, a small-molecule dual agonist of Amylin and calcitonin receptors, in 2026. The company has also obtained IND approvals from both the US FDA and China's CDE for LAE118, a selective pan-mutation PI3Kα inhibitor targeting advanced solid tumors with PIK3CA mutations. Leveraging its proven track record in successfully developing and out-licensing LAE002 (afuresertib), the company is accelerating the development of LAE118, with the goal of delivering this precision therapy to cancer patients in need of novel treatment options. The continuously expanding product pipeline underscores the company's commitment to bringing life-changing therapies to patients worldwide.